Qube Research & Technologies (QRT)’s Tvardi Therapeutics TVRD Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.4K	Buy	+10,210	New	+$32K	﹤0.01%	3223
2024 Q4	–	Sell	-1,240	Closed	-$13.7K	–	3886
2024 Q3	$13.7K	Sell	1,240 -610	-33%	-$7.15K	﹤0.01%	3006
2024 Q2	$17.2K	Buy	+1,850	New	+$44.1K	﹤0.01%	2902
2023 Q4	–	Sell	-92	Closed	-$5.55K	–	4833
2023 Q3	$5.55K	Sell	92 -2,318	-96%	-$217K	﹤0.01%	3433
2023 Q2	$246K	Buy	2,410 +1,989	+472%	+$274K	﹤0.01%	1722
2023 Q1	$74.4K	Buy	+421	New	+$141K	﹤0.01%	2178
2022 Q4	–	Sell	-874	Closed	-$295K	–	3090
2022 Q3	$295K	Sell	874 -1,226	-58%	-$444K	﹤0.01%	1629
2022 Q2	$690K	Buy	2,100 +1,627	+344%	+$571K	0.01%	1284
2022 Q1	$207K	Buy	+473	New	+$194K	﹤0.01%	1934

Other funds holding TVRD

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AFG

American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Qube Research & Technologies (QRT)'s TVRD Position: Q2 2026 in Review

Qube Research & Technologies (QRT) opened a new position in Tvardi Therapeutics (TVRD) in Q2 2026: 10,210 shares worth $19.4K. The stake represents ﹤0.01% of the portfolio and ranks #3223 among its holdings. This is a return to the name: Qube Research & Technologies (QRT) previously reported a position in TVRD as recently as Q3 2024.

Qube Research & Technologies (QRT) first reported a position in TVRD in Q1 2022 and has held it in 9 quarters since. The position peaked at $690K in Q2 2022. 57 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

Qube Research & Technologies (QRT) held 10,210 shares of Tvardi Therapeutics worth $19.4K as of Q2 2026.
Tvardi Therapeutics was a new Qube Research & Technologies (QRT) position in Q2 2026.
Tvardi Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #3223 holding.
Qube Research & Technologies (QRT) first reported a position in Tvardi Therapeutics in Q1 2022 and has held it in 9 quarters since.
Qube Research & Technologies (QRT)'s Tvardi Therapeutics position peaked at $690K in Q2 2022.
57 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.